Compare Charles River Laboratories Intl. Inc (CRL) vs iShares 3 7 Year Treasury Bond ETF (IEI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs iShares 3 7 Year Treasury Bond ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $228.76 (market cap $11.14B), while iShares 3 7 Year Treasury Bond ETF trades at $116.95. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| CRL | IEI | |
|---|---|---|
Market Cap | $11.14B | — |
Sector | Health | Fixed Income |
52-Week High | $233.60 | $120.72 |
52-Week Low | $145.57 | $116.45 |
Enterprise Value | $14.00B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
IEI, the iShares 3-7 Year Treasury Bond ETF, trades at $116.45, down 0.27% on the day. The technical outlook is bearish, with moving averages signaling a downtrend, though oscillators are neutral. Recent news highlights competition from Vanguard bond ETFs on yield and cost, while broader bond market inflows surge amid Fed policy uncertainty. The fund maintains regular dividend distributions, with recent payments around $0.36-$0.37 per share.
The outlook for IEI is cautious due to bearish technicals and competitive pressure from higher-yielding alternatives. Rising interest rate expectations pose a headwind, but its Treasury focus offers lower volatility. Key risks include Fed policy shifts and inflation persistence. Investors seeking intermediate-term government bond exposure may find stability, but yield hunters might prefer corporate or broader market ETFs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →
